The terms of the Notes, including the interest rate, initial conversion rate and other terms, will be determined upon pricing of the offering.
The Notes are being offered in connection with the Company's previously
stated plan to refinance its 9.0% Fixed Rate Term Notes due 2029 (the
"2029 Notes"). The Company intends to use the net proceeds of this
offering to redeem on the next interest payment date of
The Notes will be offered to qualified institutional buyers pursuant to
Rule 144A under the Act. Neither the Notes nor the shares of the
Company's common stock issuable upon conversion of the Notes, if any,
have been registered under the Act or the securities laws of any other
jurisdiction and may not be offered or sold in
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
Cautionary Note on Forward-Looking Statements
To the extent that statements contained in this press release are not
descriptions of historical facts, they are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements
include any statements regarding Innoviva's completion of the offering,
the anticipated principal amount of securities sold, the final terms of
the offering and Innoviva's anticipated use of proceeds, Innoviva's
ability to redeem all of the principal of its 2029 Notes and any other
statements containing the words "anticipate," "believe," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions. Such forward-looking statements involve substantial risks
and uncertainties that could cause the Company's future results,
performance or achievements to differ significantly from those expressed
or implied by the forward-looking statements. The Company undertakes no
obligation to update or revise any forward-looking statements.
Forward-looking statements should not be relied upon as representing the
Company's views as of any date subsequent to the date hereof. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company's business in
general, see the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the
Sr. Vice President and Chief Financial Officer
News Provided by Acquire Media